Anales de la RANM

24 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TRATAMIENTO NEOADYUVANTE DEL CÁNCER DE PULMÓN Mariano Provencio Pulla An RANM · Año 2019 · número 136 (01) · páginas 17 a 24 treatment of non-small cell lung cancer. Lung Cancer 2001; 32: 281-287. 13. Sugarbaker DJ, Herdon J, Kohman LJ et al. Results of cancer and leukemia group B protocol 8935: a multi- institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer-Cancer and Leukemia Group B Thoracic Surgery Group. J Thorc Cardiovasc Surg 1995; 109: 473-485. 14. Kirn DH, Lynch TJ, Mentzer SJ et al. Multimodality therapy of patients with satge IIIA, N2 non-small –cell lung cancer: impact of preoperative chemotherapy on resectability and downstaging,. J Thorac Cardiovasc Surg 1993; 106: 696-702. 15. Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan- Kettering experience with 136 patients. AnnThorc Surg 1993; 55: 1365-1374. 16. Martín N. Mediatinal lymph node dissection for lung cancer: the memorial experience. Chest Surg Clin N Am 1995; 5: 189-203. 17. Kumar P, Herdon J, Elias , et al. Comparison of pre- operative thoracic radiation therapy to pre-opetative chemotherapy on surgically staged IIIA (N2) non-small cell lung cancer: initial results of Cancer and Leucemia Group B Phase III Protocol 9134. Int J Radiat Oncol Biol Phys 1997; 39: 195. 18. Choi Y S, shim Y M, Kim J, Kim K. Recurrence-free survival and prognostic factors in resected pN2 non- small cell lung cancer. Eur J Cardiothor Surg 2002; 22: 695-700. 19. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214. 20. Martín N. Mediatinal lymph node dissection for lung cancer: The Memorial experience. Chest Surg Clin N Am 1995; 5: 189-203. 21. Johnson DH, Paul DM, Hande KR et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer - a phase II trial. J Clin Oncol 1996; 14: 2054-2060. 22. Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J, Ettinger DS. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small-cell lung cancer. SeminOncol 1995; 22 (Suppl 9): 48-54. 23. Vafai D, Israel V, Zaretsky S, Natale RB. Phase III trial of combination carboplatin and taxol in non-small-cell lung cancer (NSCLC). ProcAmSocClinOncol 1995; 14: A352. 24. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer:EORTCProtocol 07861. J ClinOncol. 1990; 8(9): 1556-1562. 25. Bonomi P, Finkelstein D, Ruckdeschel J et al. Combination Chemotherapy versus single agents followed by combination in stage IV non-small-cell lung cancer: a study of the ECOG. J Clin Oncol 1989; 7: 1602-1613. 26. Greco FA y Hainsworth JD. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced NSCLC. Semin Oncol 1997; 24: S12-17. 27. DeVore RF, Jagasia M y Johnson D. Paclitaxel by either 1-hour or 24h infusion in combination with carboplatin in advanced NSCLC. Semin Oncol 1997; 24: S27-29. 28. Palackdharry CS, Durham SJ, Durzinsky DS et al: Preliminary results of neoadjuvant paclitaxel and carboplatin in the treatment of early stage NSCLC. Semin Oncol 1997; 24: S12-34-S12-36. 29. Stroun M et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989; 46:318-322. 30. Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol 2012; 23: 1387- 1393. 31. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736. 32. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11: 7-13. 33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252- 264. 34. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61. 35. Okazaki T, Maeda A, Nishimura H et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain- containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001; 98: 13866-13871. 36. Sheppard KA, Fitz LJ, Lee JM et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/ CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004; 574: 37-41. 37. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small- cell lung cancer. J Clin Oncol 2015; 33(18): 2004-2012. 38. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454. 39. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 123-135. 40. Paz-Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non- squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33, (suppl; abstr LBA109). 41. Forde PM, Chaft JE, Smith V, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018. 24; 378(21):1976-1986. 42. Provencio M, Nadal E et al. Neo-adjuvant chemo/ immunotherapy for resectable stages IIIAnon-small cell lung cancer: Nadim Study-SLCG IASLC World Lung Cancer Congress. Toronto; 2018. Si desea citar nuestro artículo: Provencio-Pulla M. Tratamiento neoadyuvante del cáncer de pulmón ANALES RANM [Internet]. Real Academia Nacional de Medicina de España; An RANM · Año 2019 · número 136 (01) · páginas 17– 24 DOI: 10.32440/ar.2019.136.01. rev05 DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en la presente revisión.